Abstract
High mobility group box 1 (HMGB1) is released from macrophages as a late biomarker of sepsis. Conditions associated with pre-existing macrophage activation may modify HMGB1 expression. This study aimed to assess the impact of HMGB1 kinetics on 28-day mortality. In a sub-study of a previous randomized clinical trial among patients with systemic inflammatory response syndrome and gram-negative infections, patients were classified in early and late HMGB1 peak groups. Serial measurements of HMGB1, ferritin and interferon-gamma (IFNγ) were performed in all available sera. Two hundred ten patients were included; 118 (46.5%) had at least one inflammatory disease (diabetes, chronic obstructive pulmonary disease, chronic heart failure, or chronic renal disease). Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026). Co-existence of late peak and inflammatory disease synergistically impacted mortality (odds ratio of logistic regression analysis 3.17; P: 0.027). Late peak was concomitantly associated with higher values of ferritin (P = 0.035), and IFNγ (P = 0.002) among patients with hyperferritinemia. It is concluded that late HMGB1 peak was associated with worse prognosis, especially in patien...Continue Reading
References
Jul 10, 1999·Science·H WangK J Tracey
Apr 11, 2003·Arthritis and Rheumatism·Noboru TaniguchiIkuro Maruyama
Apr 20, 2004·Critical Care Medicine·R Phillip DellingerUNKNOWN Surviving Sepsis Campaign Management Guidelines Committee
Mar 9, 2005·Critical Care Medicine·Jonas Sundén-CullbergCarl Johan Treutiger
Mar 6, 2007·Critical Care Medicine·Derek C AngusUNKNOWN GenIMS Investigators
May 26, 2007·Intensive Care Medicine·Sébastien GibotPierre-Edouard Bollaert
Feb 26, 2008·Intensive Care Medicine·Sari KarlssonEsko Ruokonen
Jan 30, 2010·The Journal of Rheumatology·Jie LiXiang Chen
Jul 24, 2010·Mediators of Inflammation·Nadine UnterwalderJoerg C Schefold
Aug 13, 2010·Basic Research in Cardiology·H Christian VolzMartin Andrassy
Feb 2, 2012·Nature Reviews. Rheumatology·Helena Erlandsson HarrisDavid S Pisetsky
Dec 3, 2013·The Journal of Antimicrobial Chemotherapy·Evangelos J Giamarellos-BourboulisApostolos Armaganidis
Feb 1, 2014·Expert Opinion on Therapeutic Targets·Lori F Gentile, Lyle L Moldawer
Mar 13, 2014·Molecular Medicine·David S Pisetsky
Jun 18, 2014·Journal of Internal Medicine·A TsungT R Billiar
Jul 11, 2014·Molecular Aspects of Medicine·Rui KangDaolin Tang
Sep 30, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jaruek CharoensupSurasakdi Wongratanacheewin
Jan 23, 2016·Mediators of Inflammation·Sebastiano GangemiEgidio Imbalzano
Feb 24, 2016·JAMA : the Journal of the American Medical Association·Mervyn SingerDerek C Angus
Jan 17, 2017·Canadian Journal of Physiology and Pharmacology·Amanda M MarshDevendra K Agrawal
Jun 18, 2017·Molecular and Cellular Endocrinology·Jing ZhangPing Yang
Jul 21, 2017·Scientific Reports·Natalie E StevensKerrilyn R Diener
Aug 10, 2017·Cardiovascular Diabetology·Silvia GiovanniniAndrea Flex
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Citations
Aug 14, 2019·Shock·Feng WuRosemary A Kozar
Apr 9, 2020·Frontiers in Immunology·Huan YangUlf Andersson
Jul 19, 2020·The Journal of Surgical Research·Peng YangZhiqiang Ye
Mar 23, 2021·Surgery·Han-Jin LaiShi-Hong Wen
May 6, 2021·Scientific Reports·Hongseok YooKyeongman Jeon
May 31, 2021·Journal of Cosmetic Dermatology·Rehab Mohammed SalemRasha Shaker
Nov 23, 2021·The Kaohsiung Journal of Medical Sciences·Fu-Jing LiuDong-Yue Wei